Related Experiment Video

Updated: May 26, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors

Nobuyuki Ise1, Kazuya Omi, Daisuke Nambara

  • 1Biotechnology Research Group, Fundamental Research Department, Fujirebio Inc, Tokyo, Japan.

Anticancer Research
|December 27, 2011
PubMed
Abstract

Insights

HER2-addicted lung cancer cells respond to EGFR inhibitors, suggesting HER2 as a therapeutic target. Soluble HER2 in blood may guide treatment for these specific cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Oncogene addiction describes tumor cell dependence on oncogenes for survival, underpinning targeted therapies.
  • Epidermal growth factor receptor (EGFR) mutations predict response to EGFR inhibitors in certain cancers.
  • Alternative mechanisms of EGFR inhibitor susceptibility remain under investigation.

Purpose of the Study:

  • To investigate the susceptibility of non-small-cell lung cancer (NSCLC) cell lines to EGFR inhibitors.
  • To analyze oncogene addiction patterns and the effect of EGFR inhibitors on oncogene activation.
  • To assess the potential of oncogene protein expression as a predictive biomarker.

Main Methods:

  • Examined NSCLC cell line susceptibility to EGFR inhibitors and their oncogene addiction profiles.
  • Analyzed the impact of EGFR inhibitors on oncogene activation.
  • Assessed oncogene protein expression as a potential biomarker.

Main Results:

  • A HER2-addicted NSCLC cell line (NCI-H2170), lacking EGFR expression, showed susceptibility to EGFR inhibitors.
  • EGFR inhibitor treatment significantly reduced phosphorylation of activated HER2 and its downstream target AKT.
  • Soluble HER2 was secreted by NCI-H2170 cells and detected in mouse blood, indicating a potential biomarker.

Conclusions:

  • HER2 is a viable therapeutic target for EGFR inhibitors in HER2-addicted lung carcinomas.
  • Soluble HER2 shows promise as a biomarker for guiding treatment selection in these specific lung cancer cases.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...